NCT01275105 - A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Allergic Conjunctivitis

Interventions

DRUG

Vehicle

one drop in each eye at designated visits

DRUG

Brimonidine Tartrate 0.01%

one drop in each eye at designated visits

DRUG

Brimonidine Tartrate 0.025%

one drop in each eye at designated visits

DRUG

Oxymetazoline HCl 0.025%

one drop in each eye at designated visits

Trial Locations (1)

Ora, Inc., Andover